Raven Jaeger, M.S., RAC
Raven is the vice president of regulatory affairs at Origin Biosciences. She is focused on advancing the development of the company’s compound from nonclinical/clinical development through commercialization, ensuring global access for patients in the ultra-rare disease space. She is responsible for the overall global regulatory strategy, regulatory management, and strategic product development planning for the programs.
Raven’s experience spans over 16 years, with most of her regulatory affairs experience focused in rare diseases. She joined Origin after serving as the head of the regulatory affairs group at Leadient Biosciences (formerly Sigma-Tau Pharmaceuticals), where she developed and led the regulatory affairs and regulatory operations teams. Before joining Leadient, she worked in regulatory affairs for contract research organization ICON Clinical Research. Previously, she worked at Nabi Biopharmaceuticals, gaining experience in regulatory affairs with respect to both biologics and small molecules, including preparing for FDA advisory committee meetings and dispute resolution meetings. Raven began her career at the NIH (NIMH and Center for Scientific Review). Raven earned her M.S. in biotechnology management from the University of Maryland and B.S. in natural sciences from Johns Hopkins University. She has held a RAC in the US since 2005.